406 related articles for article (PubMed ID: 34818478)
1. Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease.
Jonasch E; Donskov F; Iliopoulos O; Rathmell WK; Narayan VK; Maughan BL; Oudard S; Else T; Maranchie JK; Welsh SJ; Thamake S; Park EK; Perini RF; Linehan WM; Srinivasan R;
N Engl J Med; 2021 Nov; 385(22):2036-2046. PubMed ID: 34818478
[TBL] [Abstract][Full Text] [Related]
2. Belzutifan: First Approval.
Deeks ED
Drugs; 2021 Nov; 81(16):1921-1927. PubMed ID: 34613603
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis.
Choueiri TK; Bauer TM; Papadopoulos KP; Plimack ER; Merchan JR; McDermott DF; Michaelson MD; Appleman LJ; Thamake S; Perini RF; Zojwalla NJ; Jonasch E
Nat Med; 2021 May; 27(5):802-805. PubMed ID: 33888901
[TBL] [Abstract][Full Text] [Related]
4. The outcome of central nervous system hemangioblastomas in Von Hippel-Lindau (VHL) disease treated with belzutifan: a single-institution retrospective experience.
Zamarud A; Marianayagam NJ; Park DJ; Yener U; Yoo KH; Meola A; Chang SD
J Neurooncol; 2023 Nov; 165(2):373-379. PubMed ID: 37955759
[TBL] [Abstract][Full Text] [Related]
5. MK-6482 as a potential treatment for von Hippel-Lindau disease-associated clear cell renal cell carcinoma.
Hasanov E; Jonasch E
Expert Opin Investig Drugs; 2021 May; 30(5):495-504. PubMed ID: 33945366
[TBL] [Abstract][Full Text] [Related]
6. Belzutifan, HIF-2α Inhibitor, and Clear Cell Renal Cell Carcinoma With Somatic Von-Hippel-Lindau Loss-of-Function Mutation.
Chan KH; Li N; Lador R; Amsbaugh M; Gonzalez A; Cen P
J Investig Med High Impact Case Rep; 2024; 12():23247096241231641. PubMed ID: 38344974
[TBL] [Abstract][Full Text] [Related]
7. Neurological applications of belzutifan in von Hippel-Lindau disease.
Zhang Y; Nguyen CC; Zhang NT; Fink NS; John JD; Venkatesh OG; Roe JD; Hoffman SC; Lesniak MS; Wolinsky JP; Horbinski C; Szymaniak BM; Buerki RA; Sosman JA; Shenoy NK; Lukas RV
Neuro Oncol; 2023 May; 25(5):827-838. PubMed ID: 36215167
[TBL] [Abstract][Full Text] [Related]
8. Belzutifan for von Hippel-Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study.
Else T; Jonasch E; Iliopoulos O; Beckermann KE; Narayan V; Maughan BL; Oudard S; Maranchie JK; Iversen AB; Goldberg CM; Fu W; Perini RF; Liu Y; Linehan WM; Srinivasan R
Clin Cancer Res; 2024 May; 30(9):1750-1757. PubMed ID: 38393723
[TBL] [Abstract][Full Text] [Related]
9. FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease-Associated Tumors.
Fallah J; Brave MH; Weinstock C; Mehta GU; Bradford D; Gittleman H; Bloomquist EW; Charlab R; Hamed SS; Miller CP; Dorff SE; Chambers WA; Mixter BD; Dinin J; Pierce WF; Ricks TK; Tang S; Donoghue M; Pazdur R; Amiri-Kordestani L; Ibrahim A; Beaver JA
Clin Cancer Res; 2022 Nov; 28(22):4843-4848. PubMed ID: 35727604
[TBL] [Abstract][Full Text] [Related]
10. Belzutifan in a Patient With VHL-Associated Metastatic Pancreatic Neuroendocrine Tumor.
Pelle E; Al-Toubah T; Morse B; Strosberg J
J Natl Compr Canc Netw; 2022 Dec; 20(12):1285-1287. PubMed ID: 36509068
[TBL] [Abstract][Full Text] [Related]
11. Belzutifan: A Narrative Drug Review.
Visweswaran V; Pavithran K
Curr Drug Res Rev; 2022; 14(2):88-95. PubMed ID: 35366789
[TBL] [Abstract][Full Text] [Related]
12. Belzutifan (MK-6482): Biology and Clinical Development in Solid Tumors.
Choi WW; Boland JL; Kalola A; Lin J
Curr Oncol Rep; 2023 Feb; 25(2):123-129. PubMed ID: 36630072
[TBL] [Abstract][Full Text] [Related]
13. Belzutifan in adults with VHL-associated central nervous system hemangioblastoma: a single-center experience.
Neth BJ; Webb MJ; White J; Uhm JH; Pichurin PN; Sener U
J Neurooncol; 2023 Aug; 164(1):239-247. PubMed ID: 37450072
[TBL] [Abstract][Full Text] [Related]
14. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
[TBL] [Abstract][Full Text] [Related]
15. Targeting hypoxia-inducible factor pathways in sporadic and Von Hippel-Lindau syndrome-related kidney cancers.
Iacovelli R; Arduini D; Ciccarese C; Pierconti F; Strusi A; Piro G; Carbone C; Foschi N; Daniele G; Tortora G
Crit Rev Oncol Hematol; 2022 Aug; 176():103750. PubMed ID: 35728738
[TBL] [Abstract][Full Text] [Related]
16. Selective HIF2A Inhibitors in the Management of Clear Cell Renal Cancer and Von Hippel-Lindau-Disease-Associated Tumors.
Suárez C; Vieito M; Valdivia A; González M; Carles J
Med Sci (Basel); 2023 Jun; 11(3):. PubMed ID: 37489462
[TBL] [Abstract][Full Text] [Related]
17. Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.
Jonasch E; McCutcheon IE; Waguespack SG; Wen S; Davis DW; Smith LA; Tannir NM; Gombos DS; Fuller GN; Matin SF
Ann Oncol; 2011 Dec; 22(12):2661-2666. PubMed ID: 22105611
[TBL] [Abstract][Full Text] [Related]
18. Sunitinib for the treatment of benign and malignant neoplasms from von Hippel-Lindau disease: A single-arm, prospective phase II clinical study from the PREDIR group.
Oudard S; Elaidi R; Brizard M; Le Rest C; Caillet V; Deveaux S; Benoit G; Corréas JM; Benoudiba F; David P; Gaudric A; Hammel P; Joly D; Timsit MO; Méjean A; Richard S
Oncotarget; 2016 Dec; 7(51):85306-85317. PubMed ID: 27852035
[TBL] [Abstract][Full Text] [Related]
19. Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort.
Jonasch E; Bauer TM; Papadopoulos KP; Plimack ER; Merchan JR; McDermott DF; Dror Michaelson M; Appleman LJ; Roy A; Perini RF; Liu Y; Choueiri TK
Eur J Cancer; 2024 Jan; 196():113434. PubMed ID: 38008031
[TBL] [Abstract][Full Text] [Related]
20. The road to systemic therapy in von Hippel-Lindau (VHL) disease: Are we there yet?
Shepherd STC; Drake WM; Turajlic S
Eur J Cancer; 2023 Mar; 182():15-22. PubMed ID: 36708612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
